The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders.

Psoriasis is an instructive example highlighting our growing knowledge about pathophysiological functions of interleukin (IL)-17. IL-17A is the predominant isoform implicated in key pathogenic features in this and other chronic inflammatory disorders. Several monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) or its IL-17RC/RA receptor (brodalumab) are currently in late stages of clinical development, where they have shown impressive efficacy. While the eponymous IL-17 has been thought to originate primarily from T helper (Th)17 cells, more recent investigations by several groups suggest that other cell types in psoriatic lesions, such as neutrophils and mast cells, are rich sources of IL-17, thus presumably contributing to the disease process to an as yet underestimated extent. This recent paradigm shift provides a plausible explanation for the rapid and strong efficacy of the novel compounds targeting IL-17 functions in psoriasis and other inflammatory disorders, and provide a more comprehensive view on the complex cytokine network in these conditions.
AuthorsMichael P Schön
JournalExperimental dermatology (Exp Dermatol) Vol. 23 Issue 11 Pg. 804-6 (Nov 2014) ISSN: 1600-0625 [Electronic] Denmark
PMID25219805 (Publication Type: Comment, Journal Article, Review)
Copyright© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Interleukin-17
  • Animals
  • Gene Expression Regulation
  • Humans
  • Interleukin-17 (immunology)
  • Mast Cells (immunology)
  • Neutrophils (immunology)
  • Psoriasis (immunology)
  • T-Lymphocyte Subsets (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: